525 related articles for article (PubMed ID: 15264875)
1. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
2. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.
von Guggenberg E; Sallegger W; Helbok A; Ocak M; King R; Mather SJ; Decristoforo C
J Med Chem; 2009 Aug; 52(15):4786-93. PubMed ID: 19591486
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand.
Wang J; Kim YS; Liu S
Bioconjug Chem; 2008 Mar; 19(3):634-42. PubMed ID: 18281926
[TBL] [Abstract][Full Text] [Related]
4. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide.
Decristoforo C; Mather SJ
Bioconjug Chem; 1999; 10(3):431-8. PubMed ID: 10346875
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical evaluation of a new indirectly labeled ⁹⁹mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide with HYNIC as bifunctional chelator.
Yu F; Lü ML; Zhang XP; Fu D; Hou M; Cai HD; Li D; Wang J; Yuan XY; Lü ZW; Dong F
Chin Med J (Engl); 2012 Jul; 125(14):2538-42. PubMed ID: 22882936
[TBL] [Abstract][Full Text] [Related]
8. A novel ternary ligand system for 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands.
Liu S; Edwards DS; Harris AR
Bioconjug Chem; 1998; 9(5):583-95. PubMed ID: 9736492
[TBL] [Abstract][Full Text] [Related]
9. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
[TBL] [Abstract][Full Text] [Related]
11. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins.
Ono M; Arano Y; Uehara T; Fujioka Y; Ogawa K; Namba S; Mukai T; Nakayama M; Saji H
Bioconjug Chem; 1999; 10(3):386-94. PubMed ID: 10346868
[TBL] [Abstract][Full Text] [Related]
12. [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation.
Babaei MH; Almqvist Y; Orlova A; Shafii M; Kairemo K; Tolmachev V
Oncol Rep; 2005 Jun; 13(6):1169-75. PubMed ID: 15870939
[TBL] [Abstract][Full Text] [Related]
13. Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands.
Liu S; Edwards DS; Looby RJ; Harris AR; Poirier MJ; Barrett JA; Heminway SJ; Carroll TR
Bioconjug Chem; 1996; 7(1):63-71. PubMed ID: 8741992
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
[TBL] [Abstract][Full Text] [Related]
15. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
16. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
[TBL] [Abstract][Full Text] [Related]
18. Technetium-binding in labelled HYNIC-peptide conjugates: role of coordinating amino acids.
Surfraz MB; King R; Mather SJ; Biagini S; Blower PJ
J Inorg Biochem; 2009 Jul; 103(7):971-7. PubMed ID: 19447500
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
